Boston Scientific Downplays Stent Compression Concerns
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific is downplaying the potential for new concerns about its drug-eluting stent systems related to stent compression, saying the complication is rare and affects all modern DES platforms.
You may also be interested in...
Boston Scientific touts stent wins. Biomet settles foreign bribery charges. Roche ups Illumina bid. Derma Sciences acquires MedEfficiency.
Data reports on obesity devices, bone density screening and more.